September 24, 2015—The senior Democrat on the House Oversight Committee asked the head of Turing Pharmaceuticals yesterday for all documents about the company’s 340B pricing of Daraprim – which Turing recently bought from another company and immediately raised the price of by over 5,000 percent.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)